# A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

> **NCT04062669** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 160 (actual)

## Conditions studied

- Virus Diseases

## Interventions

- **BIOLOGICAL:** Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
- **BIOLOGICAL:** Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
- **BIOLOGICAL:** Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
- **BIOLOGICAL:** Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
- **DRUG:** Saline Placebo
- **BIOLOGICAL:** RabAvert

## Key facts

- **NCT ID:** NCT04062669
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-13
- **Primary completion:** 2021-07-28
- **Final completion:** 2022-07-01
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04062669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04062669, "A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04062669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*